Neuroscience Trials Australia   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: Heidelberg Australia (2001)

Organization Overview

First Clinical Trial
2010
NCT00887328
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Neuroscience Trials Australia

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Amyotrophic Lateral Sclerosis (Phase 2)

Cerebral Hemorrhage (Phase 2)

Cerebral Infarction (Phase 2)

Cognitive Dysfunction (Phase 2)

Dementia (Phase 2)

Emergencies (Phase 3)

Epilepsy (Phase 2)

Hemorrhage (Phase 2)

Ischemia (Phase 2)

Motor Neuron Disease (Phase 2)

Sclerosis (Phase 2)

Seizures (Phase 2)

Stroke (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial APIs: 11